Elevated HMGB1 Levels in Neonates With Bronchopulmonary Dysplasia: A Systematic Review and Meta‐Analysis
Canadian Respiratory Journal · 2026-01 · 2026 (1)
DOI: 10.1155/carj/2816142 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Canadian Respiratory Journal, online erschienen am 13.08.2026. Verfasst von Hejia Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, First Hospital of Hebei Medical University, Shijiazhuang 050000, China, hebmu.edu.cn. Hauptthemen laut MEDLINE: HMGB1 Protein, Bronchopulmonary Dysplasia. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Commission of Hebei Province.
Abstract (Originalsprache)
Background
To assess the clinical relevance of high‐mobility group box 1 (HMGB1) in bronchopulmonary dysplasia (BPD), we conducted a systematic review and meta‐analysis comparing HMGB1 levels in neonates with and without BPD.
Methods
Eight databases (PubMed, Cochrane Library, Web of Science, Embase, CNKI, VIP, Wanfang, and CBM) were searched up to March 1, 2025. Cohort studies reporting serum or bronchoalveolar lavage fluid (BALF) HMGB1 levels in neonates were included. Meta‐analysis was performed using RevMan 5.4.
Results
Seven studies ( n = 527 neonates; 308 BPD, 219 controls) were included. HMGB1 concentrations in BALF were significantly higher in neonates with BPD than in those without BPD (mean difference [MD], 5.04 ng/mL; 95% confidence interval [CI], 4.09–5.99; p < 0.00001). Serum HMGB1 concentrations were also higher in neonates with BPD (MD, 7.24 ng/mL; 95% CI, 4.53–9.96; p < 0.00001). Subgroup analyses across postnatal time points indicated that serum HMGB1 levels tended to be higher in infants with BPD than in controls; however, the progressive increase observed from Stage I to Stage III plateaued thereafter, with no further increase in Stage IV (> 20 days).
Conclusion
Total HMGB1 concentrations in serum and BALF are elevated in neonates with BPD, which may reflect BPD‐associated inflammatory lung injury. However, the clinical utility of HMGB1 is limited by its lack of disease specificity and the inability of current assays to distinguish among biologically distinct redox isoforms. Further prospective studies are needed to clarify its diagnostic and therapeutic relevance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, First Hospital of Hebei Medical University, Shijiazhuang 050000, China, hebmu.edu.cn.
- Department of Pediatrics, Bayingolin Mongolian Autonomous Prefecture People's Hospital, Korla 841000, China.
- Department of Rodent Biology, Chifeng City Center for Disease Control and Prevention, Chifeng 024000, China.
ORCID-Profile: Hejia Li, Jiao Li, Shanshan Li, Xiaojuan Huang, Shuaiyi Li, Wenhui Wu, Yuqing Fan, Yurun Wang, Yue Zhang, Jiashun Liu, Lu Zou, Changjun Ren, Shangbin Li
Förderung
- Health Commission of Hebei Province
Zitieren
APA
Li, H., Li, J., Li, S., Huang, X., Li, S., Wu, W., Fan, Y., Wang, Y., Zhang, Y., Liu, J., Zou, L., Ren, C., & Li, S. (2026). Elevated HMGB1 Levels in Neonates With Bronchopulmonary Dysplasia: A Systematic Review and Meta‐Analysis. Canadian Respiratory Journal, 2026(1). https://doi.org/10.1155/carj/2816142
Vancouver
Li H, Li J, Li S, Huang X, Li S, Wu W, et al. Elevated HMGB1 Levels in Neonates With Bronchopulmonary Dysplasia: A Systematic Review and Meta‐Analysis. Canadian Respiratory Journal. 2026;2026(1). doi:10.1155/carj/2816142
BibTeX
@article{Li2026,
author = {Li, Hejia and Li, Jiao and Li, Shanshan and Huang, Xiaojuan and Li, Shuaiyi and Wu, Wenhui and Fan, Yuqing and Wang, Yurun and Zhang, Yue and Liu, Jiashun and Zou, Lu and Ren, Changjun and Li, Shangbin},
title = {Elevated HMGB1 Levels in Neonates With Bronchopulmonary Dysplasia: A Systematic Review and Meta‐Analysis},
journal = {Canadian Respiratory Journal},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/carj/2816142}
}
EUVIMED